Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands (DECISION)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03783429 |
Recruitment Status :
Active, not recruiting
First Posted : December 21, 2018
Last Update Posted : December 12, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Heart Failure | Drug: Digoxin Drug: Placebos | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 982 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | A national, multicenter, randomized, double-blind placebo controlled, clinical trial. |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Double blind, placebo controlled |
Primary Purpose: | Treatment |
Official Title: | Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands |
Actual Study Start Date : | July 1, 2020 |
Estimated Primary Completion Date : | July 2025 |
Estimated Study Completion Date : | July 2025 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Intervention group
The intervention group will receive low-dose digoxin
|
Drug: Digoxin
Digoxin tablets will be given orally |
Placebo Comparator: Placebo group
The placebo group will receive a matching placebo
|
Drug: Placebos
Placebo tablets will be given orally |
- Composite of repeated HF hospitalizations, urgent HF Visits, and cardiovascular death [ Time Frame: Median of 3 years ]
- All-cause mortality [ Time Frame: Median of 3 years ]
- Cardiovascular death [ Time Frame: Median of 3 years ]
- (Repeated) HF hospitalization [ Time Frame: Median of 3 years ]
- Cost-effectiveness assessed by the Medical Consumption Questionnaire [ Time Frame: Median of 3 years ]
- Urgent HF hospital visits [ Time Frame: Median of 3 years ]
- All-cause hospitalizations [ Time Frame: Median of 3 years ]
- Unscheduled cardiovascular hospital visits [ Time Frame: Median of 3 years ]
- Days alive out of hospital [ Time Frame: Median of 3 years ]
- Quality of Life assessed by the EUROQOL-5D-5L questionnaire [ Time Frame: Median of 3 years ]
Quality of Life is assessed by questions about mobility, selfcare, daily activity, pain and anxiety. The questions about mobility, selfcare and daily activity range from 'no problem doing activity' to 'not able to do activity'. The questions about pain and anxiety range from 'not at all present' to 'extremely present'.
The last question in the questionnaire asks how a person rates his or her health in the present day, ranging from 0-100, where 0 is the worst health imaginable, and 100 is the best health imaginable.
- Heart rate in both AF and sinus rhythm [ Time Frame: Median of 3 years ]
- To assess side effects (SUSARs) associated with study medication [ Time Frame: Median of 3 years ]
- Initiation of (recurrence of) AF in patients with sinus rhythm at baseline [ Time Frame: Median of 3 years ]
- Conversion to sinus rhythm and maintenance of sinus rhythm in patients with AF at baseline [ Time Frame: Median of 3 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥18year
- Outpatients with chronic HF, New York Heart Association [NYHA] class II - ambulatory IV
- LVEF<50%
-
Serum NT-proBNP concentrations:
Previous HF hospitalization ≤ 1 year before randomisation ≥400pg/mL if sinus rhythm; ≥800pg/mL if AF Previous HF hospitalization > 1 year before randomisation or in the absence of HF hospitalizations ≥ 600pg/mL if sinus rhythm; ≥1000 pg/mL if AF
BNP concentrations:
Previous HF hospitalization ≤ 1 year before randomisation ≥100pg/mL if sinus rhythm; ≥200pg/mL if AF Previous HF hospitalization > 1 year before randomisation or in absence of HF hospitalization ≥150pg/mL if sinus rhythm; ≥250pg/mL if AF.
- ≥14 days stable on guideline-recommended therapy (doses and number of therapies as tolerated by each patient)
Exclusion Criteria:
- Heart rate ≤60bpm (if sinus rhythm); heart rate ≤70bpm (if AF)
- History of HF hospitalization ≤7days
- History of myocardial infarction, myocarditis, percutaneous intervention, RCT, pacemaker/ICD implantation, cardiac surgery or stroke ≤30 days
- Estimated glomerular filtration rate (eGFR), ≤30ml/min/1.73m2
- The presence of a mechanical assist device
- Use of inotropic drugs (dopamine, dobutamine, (nor)adrenaline, and milrinon)
- Scheduled for mechanical assist device or heart transplant
- Other non-cardiac conditions with limited life expectancy (≤ duration of the study)
- Amyloid, hypertrophic obstructive or constrictive cardiomyopathy
- Accessory atrio-ventricular pathway (e.g. Wolf-Parkinson-White syndrome)
- (Intermittent) complete heart block or second-degree AV block type Mobitz without pace maker or ICD
- Severe (grade III/III) aortic valve disease
- Complex congenital heart disease
- Proven hypersensitivity to digoxin (prior side effects)
- Concomitant medication that interacts with digoxin
- Use of digoxin ≤6 months prior to inclusion
- Participation in another (intervention) clinical trial (registry studies not included)
- Women who are pregnant, breastfeeding or may be considering pregnancy during the study period
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03783429
Principal Investigator: | Michiel Rienstra, MD, PhD | University Medical Center Groningen | |
Principal Investigator: | Peter van der Meer, MD, PhD | University Medical Center Groningen | |
Principal Investigator: | Dirk J van Veldhuisen, MD, PhD | University Medical Center Groningen |
Responsible Party: | M. Rienstra, Prof. Dr., University Medical Center Groningen |
ClinicalTrials.gov Identifier: | NCT03783429 |
Other Study ID Numbers: |
DECISION trial |
First Posted: | December 21, 2018 Key Record Dates |
Last Update Posted: | December 12, 2023 |
Last Verified: | December 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Heart Failure Digoxin Atrial fibrillation |
Heart Failure Heart Diseases Cardiovascular Diseases Digoxin Anti-Arrhythmia Agents |
Cardiotonic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs |